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Abstract
We conducted a double-blind, placebo-controlled randomized
trial to assess the effect of single-dose prophylaxis using co-trim-
oxazole (960 mg) (n = 46) or ciproﬂoxacin (500 mg) (n = 43) vs.
placebo (n = 51) before urinary catheter removal on signiﬁcant
bacteriuria (SBU) (primary outcome) and urinary tract infection
(UTI) in surgical patients with scheduled bladder drainage for 3–
14 days. SBU was determined directly after catheter removal,
and UTI 12–14 days after catheter removal. After 12–14 days,
incidences of SBU were 19%, 19% and 33% for patients receiving
ciproﬂoxacin, co-trimoxazole and placebo, respectively (p ns),
and incidences of UTI were 3%, 0% and 3% for patients receiving
ciproﬂoxacin, co-trimoxazole and placebo, respectively (p ns).
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Introduction
Urinary tract infections (UTIs) account for about 40% of
nosocomial infections and about 80% of these infections are
associated with urinary catheters [1]. Opinions diverge with
respect to the use of prophylactic antibiotics upon catheter
removal [2]. A single dose of antibiotics at the time of
catheter removal was as effective in preventing UTI as a
10-day course in patients with asymptomatic bacteriuria,
and both strategies were more effective than no therapy
[3]. In our hospital it was common practice to use 3 days
of ciproﬂoxacin therapy when removing a urinary catheter,
starting 1 day before catheter removal. Because of the
absence of scientiﬁc evidence and the threat of develop-
ment of antibiotic resistance we investigated the effects of
a single-dose antibiotic regimen, before removing urinary
catheters, on the occurrence of signiﬁcant bacteriuria (SBU)
and UTI.
Methods
Patients scheduled to undergo major surgery, such as an
abdominal operation or hip surgery, were recruited from
January 2005 until December 2006 from general surgical
wards within a large teaching hospital. Urological and gynae-
cological patients were excluded. Patients with a urethral
catheter in situ for at least 3 days (72 h) were eligible. Exclu-
sion criteria were: age <18 years, pregnancy, impaired renal
or hepatic function (serum creatinine >150 mmol/L, serum
transaminases >75 IU/L), fever, UTI, antibiotic use £48 h
before urinary catheter removal, allergy to co-trimoxazole
or ciproﬂoxacin, pathology of the urogenital tract and inabil-
ity to give informed consent.
Randomization was achieved with permuted blocks of 12
numbers. The co-trimoxazole, ciproﬂoxacin and placebo
were packaged into identical opaque containers, with the
trial name and number, and number of randomization. Medi-
cation was delivered per patient directly from the pharmacy
department to the ward. The investigators were unaware of
the medication the patient was given. For control reasons
the empty bottles had to be returned to the pharmacy
department. The study was approved by the regional and
local ethics committees. Written informed consent was
obtained from all patients.
Patients were randomly assigned to receive either a single
dose of an antibiotic orally (co-trimoxazole (960 mg) or cip-
roﬂoxacin (500 mg)) or placebo 2 h before catheter removal.
Midstream urine (MSU) samples of the ﬁrst urine after cathe-
ter removal were collected. Twelve to fourteen days after
catheter removal, patients were sent a questionnaire regard-
ing UTI symptoms (dysuria, frequency and fever recorded in
the 14 days after catheter removal) and follow-up MSU sam-
ples were collected.
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases
RESEARCH NOTES INFECTIOUS DISEASES
Standard laboratory methods were used for quantitative
urine culture and the isolation, identiﬁcation and susceptibil-
ity testing of organisms. Antimicrobial susceptibility was
tested using the disk diffusion technique according to the
National Committee for Clinical Laboratory Standards.
The primary outcome measure was SBU, deﬁned as ‡104
colony-forming units (cfu)/mL (one isolate). In the case of >2
uropathogens, SBU was deﬁned as ‡105 cfu/mL in the pres-
ence of pyuria (WBC count of ‡6 per high-power ﬁeld) [4].
UTI was deﬁned as SBU at the time of follow-up in combina-
tion with symptoms or signs referable to UTI (frequency (>8
times a day) and/or dysuria, fever) in the 14 days after cathe-
ter removal.
Statistical analysis of numerical data was performed with
SPSS software (version 12.0.1). Univariate analyses using chi-
squared tests or the Fisher exact test were conducted to
assess differences in the occurrence of SBU and UTI. The
magnitude of differences was estimated by rate difference
with 95% conﬁdence intervals. To detect a difference in SBU
between groups of 33% with a signiﬁcant level of 0.05 and
statistical power of 80%, 31 patients per group were
required.
This trial was registered at http://www.clinicaltrials.gov
with the registration number NCT00126698.
Results
Eligibility for study participation was assessed in 147 patients,
of whom 140 were randomized and 115 were analysed
(Fig. 1). The three study groups were comparable in terms
of age, gender and number of catheter days (Table 1). At
catheter removal, 35% (15/43) of placebo patients had SBU
compared with 9% (3/33) of patients receiving ciproﬂoxacin
prophylaxis (p 0.01 as compared with placebo) and 27% (9/
34) of patients receiving co-trimoxazole prophylaxis (p 0.47
as compared with placebo).
Two weeks after catheter removal, there was no signiﬁ-
cant difference in SBU between patients who received pla-
cebo vs. patients who received antibiotic prophylaxis. UTI
* Reasons for the absence of second urine samples: antibiotics between first and second urine samples, patients died for other reasons, patients
forgot to deliver second urine sample, recatheterisation. 
147 patients assessed 
for eligibility
140 randomised 
7 excluded (declined to participate)
43 allocated to ciprofloxacin 
prophylaxis 
46 allocated to co-
trimoxazole prophylaxis 
51 allocated to placebo 
prophylaxis 
None lost to follow-up 
3 re-catheterisation 
2 transfer with CAD in situ 
3 antibiotics <48 h before     
catheter withdrawal 
1 withdrew consent 
None lost to follow-up 
2 re-catheterisation 
3 transfer with CAD in situ 
1 antibiotics <48 h before         
catheter withdrawal 
1 withdrew consent 
None lost to follow-up 
2 re-catheterisation 
1 died for other reasons 
1 transfer with CAD in situ 
5 antibiotics <48 h before         
catheter withdrawal 
34 analysed 
31 both urine samples and 
questionnaire 
2 only first urine sample* 
1 only second urine sample and 
questionnaire 
37 analysed 
24 both urine samples and 
questionnaire 
3 both urine samples no 
questionnaire 
10 only first urine sample* 
44 analysed 
35 both urine samples and 
questionnaire 
1 both urine samples no 
questionnaire 
8 only first urine sample* 
FIG. 1. Flow-chart of recruitment, randomization and follow-up of the trial.
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was found in one male patient (2.9%) in the placebo group,
vs. one male patient (3.2%) in the ciproﬂoxacin group
(p 0.99) and no patient in the co-trimoxazole group (p 0.99)
(Table 1). Prostatitis, pyelonephritis or other upper UTI
were not observed, and no short-term mortality was
observed due to complications of UTI.
Bacteria isolated from urine samples of patients receiving
placebo at catheter removal were mostly E. coli (44%) (12/
27) and Enterococcus faecalis (29%) (8/27). Bacteria isolated
from urine samples of patients who had received antibiotics
at catheter removal were mostly E. faecalis (57% (4/7) and
45% (5/11) for ciproﬂoxacin and co-trimoxazole, respec-
tively). In the placebo group, eight of 44 isolated microorgan-
isms (18%) were resistant to ciproﬂoxacin. Four of the
isolated microorganisms (9%) were resistant to co-trimoxaz-
ole. In the ciproﬂoxacin group, ciproﬂoxacin resistance was
found in four of 14 isolated microorganisms (29%). Resis-
tance to co-trimoxazole was found in ﬁve of the isolated
microorganisms (36%). In the co-trimoxazole group, cipro-
ﬂoxacin resistance was found in four of 16 isolated microor-
ganisms (25%). Resistance to co-trimoxazole was found in
seven of the isolated microorganisms (44%). Two weeks
after catheter removal, no signiﬁcant difference in resistance
to ciproﬂoxacin and/or co-trimoxazole was observed
between placebo and prophylaxis groups.
Discussion
The only outcome difference observed was the lower SBU
and pyuria rate 2 h after catheter removal in patients that
had received ciproﬂoxacin, as compared with those that had
received placebo. Unfortunately, urine samples were not
obtained before administration of antibiotic prophylaxis and,
therefore, a pre-existing lower prevalence of bacteriuria in
the ciproﬂoxacin group cannot be excluded. Yet, as alloca-
tion to study group occurred randomly we concur that this
difference results from chance events. Two hours after cath-
eter removal, the prevalence of SBU and pyuria tended to
be higher among patients that received co-trimoxazole than
among those that had received ciproﬂoxacin, although statis-
tical signiﬁcance was not reached. The difference in bacteri-
uria after catheter removal between patients treated with
either ciproﬂoxacin or co-trimoxazole might be explained by
a shorter time to peak concentration, which is ½–2 h for
ciproﬂoxacin and 1–4 h for co-trimoxazole.
Apart from not obtaining urine cultures before administra-
tion of antibiotics, our study also suffered from the Haw-
thorne effect. Despite daily surveillance at the participating
wards, inclusion rates of patients declined progressively dur-
ing the study as the proportion of urinary catheters removed
within 3 days after surgery increased. Although the random-
ized design prevented the occurrence of bias, these changes
in practices prolonged the inclusion period. Our study was
powered on the results from Harding et al. [3]. In that study
patients with asymptomatic bacteruria following catheter
removal either received 10 days therapy, a single dose of co-
trimoxazole, or no treatment at all. The incidence of UTI
14 days after catheter removal among patients receiving pla-
cebo was 17% in that study, which was higher than the inci-
dence of 3% observed in the present study. This might be
explained by differences in patient populations (e.g. patients
undergoing genitourinary surgery were included in Hardings’
study and excluded in the present study).
In this study the incidence of UTI within 2 weeks after
catheter removal appeared to be low in all groups, although
the power of our study is insufﬁcient to exclude a difference
between antibiotic prophylaxis and placebo in this respect. It
is improbable that prophylaxis at catheter removal would sig-
niﬁcantly affect the long-term outcome in this population
TABLE 1. Patient characteristics and effects of antibiotic prophylaxis on pyuria, SBU and UTI
Characteristics
Placebo
(n = 44)
Co-trimoxazole
960 mg (n = 37) p-value
Ciproﬂoxacin
500 mg (n = 34) p-value
Age, mean (year) 65.6 69.3 ns 69.3 ns
Age, median (range) 74.5 (41–91) 68.0 (30–91) ns 71.5 (22–89) ns
Female/male (%) 36/64 46/54 ns 56/44 ns
Median no. catheter days
(mean)
4.5 (6.5) 5.0 (6.5) ns 6.0 (6.6) ns
Analysis of urine after
catheter removal
Placebo Co-trimoxazole p-value Rate difference (%) (95% CI) Ciproﬂoxacin p-value Rate difference (%) (95% CI)
Pyuria 16/43 (37%) 9/34 (27%) ns 11 ()13; +34) 5/33 (15%) 0.04 22 (0.4; +44)
Signiﬁcant bacteriuria 15/43 (35%) 9/34 (27%) ns 8 ()15; +32) 3/33 (9%) 0.01 26 (6;+46)
Analysis of urine 2 weeks
after catheter removal
Placebo Co-trimoxazole p-value Rate difference (%) (95% CI) Ciproﬂoxacin p-value Rate difference (%) (95% CI)
Pyuria 5/36 (14%) 3/27 (11%) ns 3 ()17; +22) 2/31 (7%) ns 7 ()10; +25)
Signiﬁcant bacteriuria 12/36 (33%) 5/27 (19%) ns 15 ()10; +39) 6/13 (19%) ns 14 ()10; +38)
Symptomatic UTI 1/36 (3%) 0/24 (0%) ns 3 ()6; +12) 1/31 (3%) ns )0.4 ()12; +11)
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[5–12]. Therefore, our results do not support antibiotic pro-
phylaxis for urinary catheter removal in non-genitourinary
surgical patients.
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Abstract
From July 2007 to June 2009, all pneumococci causing invasive
pneumococcal disease in our hospital were serotyped. Antimi-
crobial susceptibility was determined by microdilution. Molecular
typing was performed by pulsed-ﬁeld gel electrophoresis and by
multilocus sequence typing. Among 251 invasive pneumococci,
serotype 8 was the most frequent (13.5%). All serotype 8 strains
were susceptible to penicillin; however, 61.8% (21/34) were
co-resistant to erythromycin, levoﬂoxacin and tetracycline and
identical to the Sweden15A-ST63 clone. Serotype 8 was signiﬁ-
cantly more frequent among human immunodeﬁciency virus
(HIV)-infected patients (36.5%). The high prevalence of this non-
conjugate vaccine multiresistant serotype 8 is a cause for con-
cern mainly in HIV-infected patients.
Keywords: HIV-infected patients, multidrug-resistant pneumo-
cocci, Streptococcus pneumoniae serotypes, vaccines
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